Form 4: 60 Degrees Pharmaceuticals Director Paul Field Reports Stock Transactions

Sentiment:

SEC Form 4


Director Paul Field reports the settlement of restricted stock units into common stock of 60 Degrees Pharmaceuticals.

Summary

  • On May 16, 2024, Paul Field, a director of 60 Degrees Pharmaceuticals, settled 4,000 restricted stock units (RSUs) into shares of common stock at a price of $0.223 per share.
  • Following the transaction, Field directly owns 14,000 shares of common stock.
  • The RSUs were initially granted on July 11, 2023, and modified on December 31, 2023, to 4,000 RSUs, which were fully vested as of December 31, 2023.
  • After the settlement, Field no longer owns any RSUs.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company director, with no inherent positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company directors.

Stakeholder Impact

  • Shareholders are informed about the director's stock transactions, promoting transparency.

Key Dates

DateDescription
07/11/2023Initial grant date of 8,000 restricted stock units (RSUs).
12/31/2023Modification date of RSUs to 4,000, fully vested.
05/16/2024Settlement date of 4,000 RSUs into common stock.
05/21/2024Date of Form 4 filing.

Keywords

Form 4, Beneficial Ownership, Director, Paul Field, 60 Degrees Pharmaceuticals, SXTP, Restricted Stock Units, Common Stock, Settlement

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.